NEUPOGEN (filgrastim) is no longer covered on the Reformulary. Reformulary covers three filgrastim biosimilars that offer the same clinical value at a lower net cost to the plan. The biosimilars, GRASTOFIL, NIVESTYM and NYPOZI are on the preferred tier (Tier 1).

Biosimilars are safe and clinically similar to the originator biologic, and have the potential to provide significant savings to you and your plan – this is essential to drug plan sustainability.

NEUPOGEN is used to treat  
Cancer-related Conditions